[Flupirtine in patients with cancer pain].

In a double-blind clinical trial the analgesic efficacy and safety of ethyl-N-(2-amino-6-[4-fluorophenyl-methylamino] pyridin-3-yl)carbamate (flupirtine, designated trademark: Katadolon) as 100-mg capsules were compared to pentazocine capsules 50 mg in 52 patients with severe to very severe cancer pain. The duration of treatment was up to one week, the daily dose up to 6 capsules. The analgesic effect was assessed by a 4-point verbal rating scale.